Pharmaceutical

EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments

Trial investigators anticipate that the FDA will decide on approval for linvoseltamab in relapsed/refractory multiple myeloma by the end of 2024.

Jun 22, 2024 - 04:00
EHA 2024: Monoclonal antibodies continue to dominate multiple myeloma treatments
Trial investigators anticipate that the FDA will decide on approval for linvoseltamab in relapsed/refractory multiple myeloma by the end of 2024.
Read the original article

Tags:

Previous Article

TYRA-200 by Tyra Biosciences for Bile Duct Cancer (Cholangiocarcinoma): Likeliho...

Next Article

Sarepta’s Elevidys secures US label expansion for DMD

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Francis deSouza’s tenure at Illumina is a lesson in how not to handle CEO succession

STAT+: Francis deSouza’s tenure at Illumina is a lesson...

Jun 12, 2023

Astellas licenses 4DMT’s AAV vector for ophthalmic targets

Astellas licenses 4DMT’s AAV vector for ophthalmic targets

Jul 11, 2023

STAT+: AbbVie buys Immunogen, maker of targeted cancer drugs, for $10 billion

STAT+: AbbVie buys Immunogen, maker of targeted cancer ...

Dec 1, 2023